TRAIL receptors as prognostic markers and survival predictors in ovarian cancer: A systematic review of clinical studies and meta-analysis.

Introduction: TRAIL cytokine (TNF-Related Apoptosis-Inducing Ligand) interacts with five receptors, four of which are expressed at the plasma membrane (DR4, DR5, DcR1, DcR2), and the fifth is a soluble osteoprotegerin receptor (OPG). Only the death receptors DR4 and DR5 contain the cytoplasmic death domain (DD), which is involved in triggering the apoptotic cascade. These receptors are found in tumor cells of various types, including ovarian cancer cells. Purpose: The aim of this article is to describe in a systematic review the presence of death receptors in cancer cells of patients and to discuss the clinical implications of this approach on various signs and clinical mechanisms of cancer. Method: The systematic review was performed on June 1, 2022, using PubMed Central - PMC, SCOPUS (Elsevier), Web of Science, Cochrane Library, and Biblioteca Virtual em Saúde - BVS (BIREME). The data were summarized in tables and critically analyzed. After the database search, five relevant studies were identified for review. Results: Analysis of these studies revealed evidence of increased survival in patients with ovarian cancer who detected these receptors in cancer tissue. In addition, we seek to understand the biological mechanisms involved in the resistance of cancer cells to TRAIL-induced apoptosis. [ABSTRACT FROM AUTHOR]